![Iomab-B](https://www.adcreviews.com/wp-content/uploads/2022/11/Iomab-B-240x93.png)
Actinium: CD45 monoclonal antibody Iomab-B III study achieves primary endpoint
On October 31, Actinium Pharmaceuticals announced that the pivotal Phase III SIERRA study of its CD45 monoclonal antibody Iomab-B (apamistamab) in patients with relapsed or